Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kai Kysenius

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Experimental Cell Research|January 12, 2016
Stress-induced upregulation of VLDL receptor alters Wnt-signaling in neuronsKai Kysenius, Henri J Huttunen
Plos One|September 6, 2014
Mitochondria and NMDA receptor-dependent toxicity of berberine sensitizes neurons to glutamate and rotenone injuryKai Kysenius, Cecilia A Brunello, Henri J Huttunen
Cellular and Molecular Life Sciences : CMLS|April 7, 2012
PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signalingKai Kysenius, Pranuthi Muggalla, Kert Mätlik, et al.
Experimental Neurology|June 16, 2018
The accumulation of enzymatically inactive cuproenzymes is a CNS-specific phenomenon of the SOD1<sup>G37R</sup> mouse model of ALS and can be restored by overexpressing the human copper transporter hCTR1James B Hilton, Kai Kysenius, Anthony R White, et al.
The Journal of Biological Chemistry|January 12, 2012
γ-Aminobutyric acid type A (GABAA) receptor activation modulates tau phosphorylationNiko-Petteri Nykänen, Kai Kysenius, Prasanna Sakha, et al.
Annals of Hematology|September 13, 2022
Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005-2016Iiro Toppila, Kai Kysenius, Tatu Miettinen, et al.
Life (Basel, Switzerland)|November 7, 2020
Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and BeyondSara Nikseresht, James B W Hilton, Kai Kysenius, et al.
Journal of Diabetes|January 26, 2024
Trends in clinical characteristics, medication use, and glycemic control in insulin-treated patients with type 1 and type 2 diabetes in Finland in 2012-2019: Nationwide real-world evidence studyLeo Niskanen, Minna Hannula, Kai Kysenius, et al.
Molecular and Cellular Neurosciences|September 22, 2009
Thyroxin regulates BDNF expression to promote survival of injured neuronsAnastasia Shulga, Anne Blaesse, Kai Kysenius, et al.
Therapeutic Advances in Urology|June 1, 2026
Characteristics, treatment patterns, and outcomes of patients with metastatic prostate cancer during 2014-2022 in Pirkanmaa, Finland-an observational studyMikko Moisander, Olivia Hölsä, Kaisa Teittinen, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Experimental Cell Research|January 12, 2016
Stress-induced upregulation of VLDL receptor alters Wnt-signaling in neuronsKai Kysenius, Henri J Huttunen
Plos One|September 6, 2014
Mitochondria and NMDA receptor-dependent toxicity of berberine sensitizes neurons to glutamate and rotenone injuryKai Kysenius, Cecilia A Brunello, Henri J Huttunen
Cellular and Molecular Life Sciences : CMLS|April 7, 2012
PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signalingKai Kysenius, Pranuthi Muggalla, Kert Mätlik, et al.
Experimental Neurology|June 16, 2018
The accumulation of enzymatically inactive cuproenzymes is a CNS-specific phenomenon of the SOD1<sup>G37R</sup> mouse model of ALS and can be restored by overexpressing the human copper transporter hCTR1James B Hilton, Kai Kysenius, Anthony R White, et al.
The Journal of Biological Chemistry|January 12, 2012
γ-Aminobutyric acid type A (GABAA) receptor activation modulates tau phosphorylationNiko-Petteri Nykänen, Kai Kysenius, Prasanna Sakha, et al.
Annals of Hematology|September 13, 2022
Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005-2016Iiro Toppila, Kai Kysenius, Tatu Miettinen, et al.
Life (Basel, Switzerland)|November 7, 2020
Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and BeyondSara Nikseresht, James B W Hilton, Kai Kysenius, et al.
Journal of Diabetes|January 26, 2024
Trends in clinical characteristics, medication use, and glycemic control in insulin-treated patients with type 1 and type 2 diabetes in Finland in 2012-2019: Nationwide real-world evidence studyLeo Niskanen, Minna Hannula, Kai Kysenius, et al.
Molecular and Cellular Neurosciences|September 22, 2009
Thyroxin regulates BDNF expression to promote survival of injured neuronsAnastasia Shulga, Anne Blaesse, Kai Kysenius, et al.
Therapeutic Advances in Urology|June 1, 2026
Characteristics, treatment patterns, and outcomes of patients with metastatic prostate cancer during 2014-2022 in Pirkanmaa, Finland-an observational studyMikko Moisander, Olivia Hölsä, Kaisa Teittinen, et al.
Pageof 4